
Sedana Medical Q3 - A blow but no curtains-down event

Redeye lowers its fair value range following a reconsideration of its financial estimates (following the shifted US launch timeline) and an increased WACC. We argue that investor interest in the share is bound to be low for some time, but its long-term US prospects are still intriguing.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Sedana Medical Q3 - A blow but no curtains-down event](#)